Top

Magnetic Resonance Materials in Physics, Biology and Medicine

Published in:

Open Access 01-02-2013 | Research Article

PET/MR for therapy response evaluation in malignant lymphoma: initial experience

Authors: Ivan Platzek, Bettina Beuthien-Baumann, Jens Langner, Manuel Popp, Georg Schramm, Rainer Ordemann, Michael Laniado, Jörg Kotzerke, Jörg van den Hoff

Published in: Magnetic Resonance Materials in Physics, Biology and Medicine | Issue 1/2013

Abstract

Object

To evaluate the feasibility of positron emission tomography/magnetic resonance imaging (PET/MR) with ¹⁸fluoro-2-deoxyglucose (FDG) for therapy response evaluation of malignant lymphoma.

Materials and methods

Nine patients with malignant lymphoma who underwent FDG-PET/MR before and after chemotherapy were included in this retrospective study. Average time between the two scans was 70 days. The scans were evaluated independently by two nuclear medicine physicians. The Ann Arbor classification was used to describe lymphoma stage. Furthermore, the readers also rated PET image quality using a five point scale. Weighted kappa (κ) was used to calculate interrater agreement.

Results

The initial scan showed foci of increased FDG uptake in all patients, with Ann Arbor stage varying between I and IV. In the follow-up examination, all but one patient showed complete response to chemotherapy. PET image quality was rated as very good or excellent for all scans. Interrater agreement was excellent regarding Ann Arbor stage (κ = 0.97) and good regarding image quality (κ = 0.41).

Conclusion

PET/MR shows promising initial results for therapy response evaluation in lymphoma patients.

Swerdlow SH, International Agency for Research on Cancer, World Health Organization (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours, 4th edn. International Agency for Research on Cancer, Lyon, France

Kwee TC, Kwee RM, Nievelstein RA (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood 111(2):504–516PubMedCrossRef

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578PubMedCrossRef

Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy–is biopsy of FDG-avid lesions still needed? Radiology 244(1):257–262PubMedCrossRef

Czernin J, Allen-Auerbach M, Schelbert HR (2007) Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 48(Suppl 1):78S–88SPubMed

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET/CT scanner for clinical oncology. J Nucl Med 41(8):1369–1379PubMed

Zaidi H, Ojha N, Morich M, Griesmer J, Hu Z, Maniawski P, Ratib O, Izquierdo-Garcia D, Fayad ZA, Shao L (2011) Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol 56(10):3091–3106PubMedCrossRef

Schramm G, Beuthien-Baumann B, Hoffheinz F, Langner J, Petr J, Platzek I, Steinbach J, Kotzerke J, van den Hoff J (2012) Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole body PET MR system: a direct comparison with transmission-based attenuation correction. MAGMA (this issue)

Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31(11):1860–1861PubMed

10.

Nievelstein RA, Quarles van Ufford HM, Kwee TC, Bierings MB, Ludwig I, Beek FJ, de Klerk JM, Mali WP, de Bruin PW, Geleijns J (2012) Radiation exposure and mortality risk from CT and PET imaging of patients with malignant lymphoma. Eur Radiol. doi:10.1007/s00330-012-2447-9

11.

Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, Nekolla SG, Ziegler S, Ganter C, Rummeny EJ, Schwaiger M (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53(6):845–855PubMedCrossRef

12.

van Ufford HM, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R, Nievelstein RA, de Klerk JM (2011) Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. Am J Roentgenol 196(3):662–669CrossRef

13.

Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL (2011) Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 197(3):W384–W391PubMedCrossRef

Title: PET/MR for therapy response evaluation in malignant lymphoma: initial experience
Authors: Ivan Platzek
Bettina Beuthien-Baumann
Jens Langner
Manuel Popp
Georg Schramm
Rainer Ordemann
Michael Laniado
Jörg Kotzerke
Jörg van den Hoff
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Magnetic Resonance Materials in Physics, Biology and Medicine / Issue 1/2013
Print ISSN: 0968-5243
Electronic ISSN: 1352-8661
DOI: https://doi.org/10.1007/s10334-012-0342-7

At a glance: The STEP trials

Springer Medicine

PET/MR for therapy response evaluation in malignant lymphoma: initial experience

Abstract

Object

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Object

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting

Does PET/MR in human brain imaging provide optimal co-registration? A critical reflection

PET/MRI in cancer patients: first experiences and vision from Copenhagen

Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer’s perspective

Radiotracers for positron emission tomography imaging

MRI for attenuation correction in PET: methods and challenges